SCHEMBL722692

SCHEMBL722692

COCNC(=O)c1csc(-c2ccccc2)n1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.64
CYP1A2 P05177 1/20 0.64
CYP3A4 P08684 1/20 0.64
CYP2C9 P11712 1/20 0.64
CYP2C19 P33261 1/20 0.64
HDAC1 Q13547 1/20 0.63
HDAC8 Q9BY41 1/20 0.63
HDAC6 Q9UBN7 1/20 0.63
HPGDS O60760 2/20 0.61
TDP1 Q9NUW8 2/20 0.60
TLR7 Q9NYK1 2/20 0.56
MAPT P10636 3/20 0.55
ATM Q13315 2/20 0.55
NPSR1 Q6W5P4 2/20 0.55
L3MBTL1 Q9Y468 2/20 0.55
NPY1R P25929 1/20 0.55
NPY2R P49146 1/20 0.55
ACKR3 P25106 2/20 0.55
LMNA P02545 2/20 0.52
KDM4E B2RXH2 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12789158 0.85 HPGD (0.69) HPGDCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL11511135 0.83 HDAC1 (0.74) HPGDCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL3436271 0.82 HPGD (0.66) HPGDCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL12790089 0.82 HPGD (0.69) HPGDCYP1A2CYP3A4CYP2C9CYP2C19
Hydrazine SCHEMBL27906351 0.81 HDAC1 (0.72) HPGDCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL12279458 0.80 MAOA (0.65) HPGDCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL13407997 0.80 HPGD (0.77) HPGDCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL27966332 0.80 HPGD (0.66) HPGDCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL19294366 0.79 HDAC1 (0.56) HPGDCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL12790012 0.79 HPGDS (0.72) HPGDCYP1A2CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-06-12 US disclosed
US-12187720-B2 Compounds for treatment of cancer UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-01-07 US disclosed
US-11465987-B2 Compounds for treatment of cancer Oncternal Therapeutics, Inc. (US) 2022-10-11 US disclosed
EP-3289876-B1 COMPOUNDS FOR TREATMENT OF CANCER UNIV TENNESSEE RES FOUND (US) 2022-07-20 EP disclosed
US-20220024912-A1 COMPOUNDS FOR TREATMENT OF CANCER Oncternal Therapeutics, Inc. (US) 2022-01-27 US disclosed
US-11084811-B2 Compounds for treatment of cancer Oncternal Therapeutics, Inc. (US) 2021-08-10 US disclosed
US-10865196-B2 Compounds for treatment of cancer UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2020-12-15 US disclosed
US-10301285-B2 Compounds for treatment of cancer GTX, INC. (US) 2019-05-28 US disclosed
US-20190092755-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2019-03-28 US disclosed
EP-2608671-B1 COMPOUNDS FOR TREATMENT OF CANCER GTX INC (US) 2018-12-12 EP disclosed
WO-2012027481-A9 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2013-10-10 WO disclosed
US-20130197049-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2013-08-01 US disclosed
EP-2608671-A1 COMPOUNDS FOR TREATMENT OF CANCER Gtx, Inc. (US) 2013-07-03 EP disclosed
CN-102883607-A Compounds for the treatment of cancer GTX INC (US) 2013-01-16 CN disclosed
EP-2542081-A1 COMPOUNDS FOR TREATMENT OF CANCER Gtx, Inc. (US) 2013-01-09 EP disclosed
US-20120071524-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2012-03-22 US disclosed
WO-2012027481-A1 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2012-03-01 WO disclosed
US-20110257196-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2011-10-20 US disclosed
WO-2011109059-A1 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2011-09-09 WO disclosed
US-20090326020-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2009-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187720-B2 Compounds for treatment of cancer KLK3, BRDT, ACP3 HPGD 522/4885CYP1A2 4356/4885CYP3A4 4225/4885
US-20090326020-A1 COMPOUNDS FOR TREATMENT OF CANCER HCCS, NQO1, CCNY HPGD 116/4885CYP1A2 133/4885CYP3A4 366/4885
US-20120071524-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 HPGD 522/4885CYP1A2 4356/4885CYP3A4 4225/4885
US-10865196-B2 Compounds for treatment of cancer CYP19A1, CYP17A1, SOX18 HPGD 661/4885CYP1A2 38/4885CYP3A4 410/4885
US-10301285-B2 Compounds for treatment of cancer CYP19A1, CYP17A1, SOX18 HPGD 661/4885CYP1A2 38/4885CYP3A4 410/4885
US-20130197049-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 HPGD 522/4885CYP1A2 4356/4885CYP3A4 4225/4885
US-11084811-B2 Compounds for treatment of cancer KLK3, BRDT, ACP3 HPGD 522/4885CYP1A2 4356/4885CYP3A4 4225/4885
US-20220024912-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 HPGD 522/4885CYP1A2 4356/4885CYP3A4 4225/4885
US-20110257196-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 HPGD 522/4885CYP1A2 4356/4885CYP3A4 4225/4885
US-20190092755-A1 COMPOUNDS FOR TREATMENT OF CANCER CYP19A1, CYP17A1, SOX18 HPGD 661/4885CYP1A2 38/4885CYP3A4 410/4885
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 HPGD 522/4885CYP1A2 4356/4885CYP3A4 4225/4885
US-11465987-B2 Compounds for treatment of cancer KLK3, BRDT, ACP3 HPGD 522/4885CYP1A2 4356/4885CYP3A4 4225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.